Subcutaneous immunoglobulin for patients with antibody deficiency

British Journal of Hospital Medicine

Volumn 68, Issue 4, 2007, Pages 206-210

  Helbert, Matthew ^a   Farragher, Alex ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; UNCLASSIFIED DRUG; VIVAGLOBIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG TOLERABILITY; GASTROINTESTINAL INFECTION; HOME CARE; HUMAN; HUMORAL IMMUNE DEFICIENCY; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; REVIEW; UNSPECIFIED SIDE EFFECT; X LINKED AGAMMAGLOBULINEMIA;

EID: 34247373138     PISSN: 17508460     EISSN: None     Source Type: Journal    
DOI: 10.12968/hmed.2007.68.4.206     Document Type: Review

References (25)

1. Barandun S, Isliker H (1986) Development of immunoglobulin preparations for intravenous use. Vox Sanguinis 51(2): 157-60
2. Berger M (2004) Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 112: 1-7
3. Berger M, Cupps TR, Fauci AS (1980) Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann Int Med 93(1): 55-6
4. Berger M, Cupps TR, Fauci AS (1982) High-dose immunoglobulin replacement therapy by slow subcutaneous infusion during pregnancy. JAMA 247(20): 2824-5
5. Blore J, Haeney M (1989) Primary antibody deficiency and diagnostic delay. BMJ 298: 516-17
6. Brennan VM, Salome-Bentley NJ, Chapel HM (2003) Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol 133: 247-51
7. Champi C (2002) Primary immunodeficiency disorders in children: prompt diagnosis can lead to lifesaving treatment. J Paed Health Care 16(1): 16-21
8. Chapel HM (1994) Consensus on diagnosis and management of primary antibody deficiencies. BMJ 308: 581-5
9. Chapel HM, Spickett GP, Ericson D et al (2000) The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 20(2): 94-9
10. CSL Behring UK Ltd (2005) Vivaglobin product monograph. CSL Behring UK Ltd, Haywards Heath, West Sussex
11. Cunningham-Rundles C, Bodian C (1999) Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 92(1): 34-48
12. Eijkhout HW, Van der Meer JW, Kallenberg CG et al (2001) The effect of two differenr dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. Ann Int Med 135(3): 165-74
13. Gardulf A, Andersen V, Bjorkander J et al (1995) Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 345: 365-9
14. Gardulf A, Nicolay U, Asensio O et al (2004) Children and adults in primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 114(4): 936-42
15. Gaspar J, Gerritsen B, Jones A (1998) Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child 79: 48-51
16. Immune Deficiency Foundation (2003) Treatment Experiences and Preferences of Patients with Primary Immune Deficiency Disease: First National Survey. Immune Deficiency Foundation, Towson, Maryland, USA
17. Leahy MF (1986) Subcutaneous immunoglobulin home treatment hypogammaglobulinemia. Lancet ii: 48
18. Liese JG, Wintergerst U, Tympner KD, Belohradsky B H, Klaus D, Bernd H (1992) High- vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. Am J Dis Children 146: 335-9
19. Nicolay U, Haag S, Eichmann F, Herget S, Spruck D, Gardulf A (2005) Measuring treatment satisfaction in patients with primary immunodeficiency disease receiving lifelong immunoglobulin replacement therapy. Qual Life Res 14(7): 1683-91
20. Nicolay N, Kiessling P, Berger M et al (2006) Health-related quality of life and trearment satisfaction in North American patients with primary immunodeficiency disease receiving subcutaneous IgG self-infusions at home. J Clin Immunol 26(1): 65-72
21. Radinsky S, Bonagura C (2003) Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin. J Allergy Clin Immunol 112: 630-3
22. Remvig L, Andersen V, Hansen NE et al (1991) Prophylactic effect of self-administered pump-driven subcutaneous IgG infusion in patients with antibody deficiency: a triple-blind cross-over srudy comparing P-IgG levels of 3 gl versus 6gl. J Int Med 229: 73-7
23. Spickett GP, Chapel HC (1996) Report on the audit of patients with primary antibody deficiency in the United Kingdom. Qual Health Care 4(4): 263-8
24. Stiehm ER, Casillas AM, Finkelstein JZ et al (1998) Slow subcutaneous human intravenous immunoglobulin in the trearment of antibody immunodeficiency: use of an old method with a new product. J Allergy Clin Immunol 101: 848-9
25. Welch MJ, Stiehm ER (1983) Slow subcutaneous immunoglobulin therapy in a patient with reactions to intramuscular immunoglobulin. J Clin Immunol 3(3): 285-6